Abstract
Localized scleroderma (LS) is clinically characterized by idiopathic fibrosis of localized skin and subcutaneous tissues. No reliable assessments of disease severity are available for LS. Several outcome measures have been proposed in recent publications, such as semiquantitative scoring system and computer-based scoring method. The performance of laser doppler flowmetry, super sound, and magnetic resonance have been explored in the measurement of disease severity of LS. Recent advances in therapy of this disease mainly focus on immunomodulators and anti-fibrosis agents. Some new treatment options for LS, such as tacrolimus, imiquimod, methotrexate, bosentan, phototherapy with UVA light, have been introduced and their efficacy has been estimated. This article reviews advances in disease severity measures and therapy of LS. Key words: Scleroderma,limited; Drug therapy; Phototherapy; PUVA therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Dermatology and Venereology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
